ABOUT 3TR
3TR-ABC is a new European study, which focuses on the effectiveness of biological treatment
on patients with severe asthma.
An estimated 250-300 million people suffer from asthma worldwide,
and about 5-10% of these can be categorised as having severe asthma.
Ground-breaking new treatment options now exist in the form of biological therapies however,
with these new options, new questions also raises!
THE STUDY
DESIGN
The 3TR-ABC study is a multicentre observational prospective cohort study that follows patients with severe asthma from the start of biological therapy and three years onwards.
The study is a part of the European IMI research consortium 3TR, aiming to provide new insights into disease mechanisms in a range of immune diseases, including asthma. The study is designed as an umbrella platform study, consisting of multiple study arms that adhere to the same master protocol.
All study arms have the same aims, inclusion and exclusion criteria, and sampling of core data and biologic material.
In addition, some sites may be able to collect more advanced samples, or they may wish to add a sub-study.
THE STUDY
AIM
The aim of the study is to assess responses to treatment with current biologics, to uncover immunological mechanisms that might be new treatment targets in severe asthma.
Patients will be extensively characterized at baseline and then followed throughout the years with formal clinical and biological assessment at 4, 16, 52 weeks, and 2, 3 years.
Based on the response to treatment, patients will be stratified into groups.
Pre-treatment biomarker profiles obtained at the baseline visit will be compared, as well as the immunological response to treatment.
Healthy individuals and patients with mild/moderate controlled asthma are included as reference groups and will undergo the same baseline visits as patients with severe asthma.
Several bio-samples, to perform multi-omic analysis, will be taken to examine biological pathways associated with response and non-response.
GOVERNANCE
STRUCTURE
The 3TR-ABC Study is governed by multiple committees, groups, teams and boards in order to secure the interest of all partners.
The Steering Committee provides the strategic leadership and oversight of the study and functions as the highest authorisation. The Research Committee is responsible for driving 3TR-ABC research strategies and ensuring synergies/promoting collaborations between 3TR-ABC researchers.
Executive operational leadership is provided by the Core Management Group while the Study Management & Coordination Hub provide practical support in every aspect of the study from study management to bioresource management, data management and research management. Furthermore, close interaction and communication is valued with both the 3TR Consortium including Work package (WP) 8, academia and industry.
The study receives management support from European Respiratory Society (ERS) and the 3TR Consortium.
THE CHAIRS OF
THE STUDY
co-chair
Professor, Head of Respiratory Research Unit, Bispebjerg Hospital, Copenhagen, Denmark
co-chair
Professor, Precision Medicine in Respiratory Disease, Academic Medical Center, Amsterdam, The Netherland